OA
VRTX icon

Oak Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Oak Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Hold
4,677
– – 0.14% 80
2025
Q4 		$2.12M Sell
4,677
-94
-2% -$40.5K 0.13% 74
2025
Q3 		$1.87M Hold
4,771
– – 0.11% 77
2025
Q2 		$2.12M Hold
4,771
– – 0.14% 70
2025
Q1 		$2.31M Buy
4,771
+200
+4% +$93.2K 0.17% 66
2024
Q4 		$1.84M Sell
4,571
-188
-4% -$87.1K 0.13% 80
2024
Q3 		$2.21M Hold
4,759
– – 0.15% 71
2024
Q2 		$2.23M Sell
4,759
-100
-2% -$43.4K 0.15% 71
2024
Q1 		$2.03M Sell
4,859
-1,998
-29% -$845K 0.14% 81
2023
Q4 		$2.79M Sell
6,857
-357
-5% -$132K 0.21% 62
2023
Q3 		$2.51M Sell
7,214
-220
-3% -$76.9K 0.21% 62
2023
Q2 		$2.62M Sell
7,434
-582
-7% -$196K 0.21% 66
2023
Q1 		$2.53M Buy
8,016
+1,088
+16% +$326K 0.21% 67
2022
Q4 		$2M Buy
6,928
+700
+11% +$213K 0.17% 86
2022
Q3 		$1.8M Hold
6,228
– – 0.15% 76
2022
Q2 		$1.75M Hold
6,228
– – 0.14% 80
2022
Q1 		$1.63M Sell
6,228
-178
-3% -$42.2K 0.1% 89
2021
Q4 		$1.41M Sell
6,406
-500
-7% -$97.2K 0.07% 98
2021
Q3 		$1.25M Hold
6,906
– – 0.07% 94
2021
Q2 		$1.39M Sell
6,906
-291
-4% -$60.9K 0.08% 91
2021
Q1 		$1.55M Buy
7,197
+147
+2% +$32.3K 0.09% 89
2020
Q4 		$1.67M Sell
7,050
-12,090
-63% -$2.77M 0.1% 88
2020
Q3 		$5.21M Buy
19,140
+60
+0.3% +$16.6K 0.35% 53
2020
Q2 		$5.54M Buy
+19,080
New +$5.17M 0.37% 53

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Oak Associates's VRTX Position: Q1 2026 in Review

Oak Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 4,677 shares worth $2.09M. The position accounts for 0.14% of the portfolio, ranked #80.

Oak Associates first reported a position in VRTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $5.54M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Oak Associates held 4,677 shares of Vertex Pharmaceuticals worth $2.09M as of Q1 2026.
  • Oak Associates left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.14% of Oak Associates's portfolio in Q1 2026, its #80 holding.
  • Oak Associates first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Oak Associates's Vertex Pharmaceuticals position peaked at $5.54M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.